Latest From Sectra AB
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
The global market for osteoporosis diagnostic products is expected to expand from $253m in 2015 to $304m by 2020, fueled by a rising aging population and the need to test for osteoporosis and associated fracture risk. This article offers an in-depth look at the growth markets for both bone densitometer testing and biochemical marker tests, as well as the evolving competitive landscape, and the drivers and barriers to market entry.
Several new modalities are poised to change the way breast cancer screenings and diagnostics are performed as physicians and patients continue to search for technologies that can do more than standard X-rays. Ultrasound, computed tomography, and 3-D imaging are being touted as ways to improve the detection of tumors – especially in women with dense breast tissue – as well as to reduce exposure to radiation. Currently, the market is dominated by large, established manufacturers, but some new players are bringing in innovative options that are poised to push the field forward.
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Pacs (Picture Archive & Communications Systems)
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- Sectra AB
- Senior Management
Torbjorn Kronander, PhD, Pres. & CEO
Simo Pykalisto, CFO
Marie Ekström, Pres. business area Imaging IT Solutions
- Contact Info
Phone: 13 23 52 00
Linkoping, SE-583 30
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.